Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor
Remi Adelaiye‐Ogala(Roswell Park Comprehensive Cancer Center), David James VanderWeele(Northwestern University), Adlai R. Grayson(Center for Cancer Research), Kathleen Kelly(National Cancer Institute), Brian J. Capaldo(University of Virginia), Jose Antonio Rodriguez-Nieves(University of Massachusetts Boston), Supreet Agarwal(University of Iowa), Aian Neil Alilin(National Cancer Institute), Yen Thi Minh Nguyen(Center for Cancer Research), Michael L. Beshiri(National Cancer Institute), Berkley E. Gryder(University School), Keith H. Jansson(National Cancer Institute)
Cited by 5
Related Papers
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
|Cancer Discovery|2017|336
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
|Clinical Cancer Research|2018|236
Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
|Nature Genetics|2019|182